ARUP is accepting COVID-19 molecular test orders. If your available quantities in eSupply are insufficient for your needs, please contact Client Services at (800) 522-2787.

Read more here about ARUP’s response to COVID-19.

Ordering Recommendation

Use to detect the 2019 novel coronavirus (SARS-CoV-2), influenza A/B virus, and RSV virus.

Mnemonic
FLUCOVRSV
Methodology

Qualitative Nucleic Acid Amplification

Performed

Daily

Reported

1-4 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Nasopharyngeal swab.
Also acceptable: Oropharyngeal swab, nasal swab.
Refer to the "COVID-19 Specimen Collection Guide" at https://www.aruplab.com/infectious-disease/coronavirus/testing

Specimen Preparation

Nasopharyngeal swab: Place in viral transport media (ARUP supply #12884) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at(800) 522-2787, Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag.
Oropharyngeal or nasal swab: Place in viral transport media (ARUP supply #12884) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787, Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag.

Storage/Transport Temperature

Frozen

Unacceptable Conditions

Swabs not in media. Wood swabs, calcium alginate swabs. Media with guanidine-containing materials, 'molecular media' that indicates inactivation of pathogens and preservation of RNA/DNA, charcoal media. Specimens sent in tubes with pop-top lids/caps. Specimens in glass tubes.

Remarks

Specimen source required.

Stability

Swabs: Ambient: Unacceptable; Refrigerated: 2 days; Frozen: 1 month

Reference Interval
Interpretive Data

This test is intended for the qualitative detection and differentiation of 2019 novel coronavirus SARS-CoV-2, influenza A/B virus, and/or RSV virus RNA from individuals suspected of respiratory viral infection.

Not Detected results do not rule out the presence of PCR inhibitors in the patient specimen or assay-specific nucleic acid in concentrations below the level of detection by the assay.

Detected results are indicative of the presence of SARS-CoV-2, influenza A/B, or RSV virus RNA. Due to the complexity of nucleic acid amplification methodologies, there may be a risk of false-positive results. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.

Reliable results are dependent on adequate specimen collection, transport, storage, and handling.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

This test detects and differentiates RNA from 2019 novel coronavirus SARS-CoV-2, influenza A/B virus, and RSV virus. This test does NOT differentiate between influenza A or B.

Hotline History
N/A
CPT Codes

87637

Components
Component Test Code* Component Chart Name LOINC
3003444 Influenza, SARS-CoV-2, and RSV Source 31208-2
3003446 Influenza by NAA 62462-7
3003447 SARS-CoV-2 by NAA 94500-6
3003448 RSV by NAA 40988-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • 2019-nCoV
  • Coronavirus disease - 2019
  • COVID-19 Illness
  • COVID-2019
  • Influenza
  • Influenza A and B
  • Respiratory Syncytial Virus, RSV
  • RSV Molecular Detection, PCR
  • RSV PCR
  • SARS-CoV-2
  • Wuhan
Influenza, SARS-CoV-2, and RSV by NAA